Hey Gold, I see exactly what you're saying. But it's possible that those specimen samples didn't produce CEA values, FDP values, or either of the two values.
"(approximately 50 of the originally provided biospecimens did not provide any values so the final data set included 926 samples)"
It's unclear about what "values" they are referring to exactly. They also failed to mention the absolute percentages for stage I and II detection. I am very curious as to what those values are.
Regardless, whatever advantage Onko Sure has over CEA, there is no way to get this test running with the apparent financial turmoil within RPC.
Thanks for the info, Gold.
